INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER C

This Interim Report contains forward-looking statements

and estimates with respect to the anticipated future performance of MDxHealth SA and its wholly-owned subsidiaries (hereinafter "mdxhealth"

or the "Company") and the market in which it operates. Such statements and estimates are based on assumptions and assessments

of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events

are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different.

Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking

statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible

effects on our operations, and the demand for the Company's products; the Company's ability to successfully and profitably

market its products; the acceptance of its products and services by healthcare providers; the willingness of health insurance companies

and other payers to cover its products and services and adequately reimburse us for such products and services; and the amount and nature

of competition for its products and services. Mdxhealth expressly disclaims any obligation to update any such forward-looking statements

in this Interim Report to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances

on which any such statement is based unless required by law or regulation. This Interim Report does not constitute an offer or invitation

for the sale or purchase of securities or assets of mdxhealth in any jurisdiction. No securities of mdxhealth may be offered or sold within

the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,

and in accordance with any applicable U.S. securities laws.

Key non-audited financials, as of June 30,

Key unaudited consolidated figures for the six

months ended June 30, 2022 (thousands of US dollars, except per share data):

Total revenue for the first half of 2022 was $13.0

million compared to total revenue of $10.7 million for the first half of 2021, an increase of 21%. Services revenue amounted to $13.0

million, an increase of 24% as compared to $10.5 million a year earlier.

Gross profit on products and services for the

first half of 2022 was $5.8 million as compared to $5.2 million for the first half of 2021. Gross margins on products and services declined

to 44.4% for the first half of 2022 as compared to 48.6% for the same period in 2021, primarily due to timing of cash receipts for our

UTI test, which is expected to reverse in the second half of 2022. In addition, we expect coverage of our Select mdx test, as well as

our recently acquired Oncotype GPS business, to contribute further to gross margin growth in the second half of 2022.

Operating expenses in the first half of 2022 were

$22.8 million versus $17.7 million for the first half of 2021, primarily due to additional public company expenses as a result of the

Operating loss and net loss for the first half

of 2022 were $17.0 million and $18.1 million, respectively, with losses increasing compared to $12.4 million and $13.3 million, respectively,

over the same period in 2021, for the reasons stated above.

Justification to continue using the accounting

rules on the basis of going concern

The Company has experienced net losses and significant

cash used in operating activities since its inception in 2003, and as of June 30, 2022, had an accumulated deficit of $262.4 million,

a net loss of $18.1 million, and net cash used in operating activities of $15.1 million. Management expects the Company to continue to

incur net losses and have significant cash outflows for at least the next twelve months. While these conditions, among others, could raise

doubt about its ability to continue as a going concern, these consolidated financial statements have been prepared assuming that the Company

will continue as a going concern. This basis of accounting contemplates the recovery of its assets and the satisfaction of liabilities

in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive

cash flows adequate to support the Company's cost structure.

As of June 30, 2022, the Company had cash and

cash equivalents of $40.0 million. Taking into account the above financial situation and on the basis of the most recent business plan,

the Company believes that it has sufficient cash to be able to continue its operations for at least the next twelve months from the date

of issuance of these financial statements, and accordingly has prepared the consolidated financial statements assuming that it will continue

as a going concern. This assessment is based on forecasts and projections within management's most recent business plan, which takes

into account the Company's acquisition of the Oncotype DX GPS business from Exact Sciences (discussed further in Footnote 10 -

Subsequent Events) as well as the Company's expected ability to realize cost reductions should these forecasts and projections not

Principal risks related to the business

The principal risks related to the mdxhealth's

business activities have been outlined in the 2021 Annual Report, which is available on the internet at www.mdxhealth.com/investors/financials

Declaration of responsible persons

The Board of Directors of MDxHealth SA, represented

by all its members, declares that, as far as it is aware, the financial statements in this Interim Report, made up according to the applicable

standards for financial statements, give a true and fair view of the equity, financial position and the results of the company and its

consolidated companies. The Board of Directors of MDxHealth SA, represented by all its members, further declares that this Interim Report

gives a true and fair view on the information that has to be contained herein. The condensed consolidated interim financial statements

have been prepared in accordance with International Accounting Standard (IAS) 34 (Interim Financial Reporting) as issued by the International

Accounting Standards Board, or IASB, and as adopted by the EU.

II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended June 30, 2022

In thousands of USD (except per share data)

Condensed unaudited consolidated statement of profit or loss

Attributable to owners of MDxHealth SA

MDxHealth, SA together with its subsidiaries are

herein referred to as "mdxhealth" or the "Company". Mdxhealth is a company domiciled in Belgium, with offices

and labs in the United States and The Netherlands. The reporting and functional currency of the Company is the U.S. Dollar.

The condensed consolidated interim financial statements

have been prepared in accordance with International Accounting Standard (IAS) 34 - Interim Financial Reporting, as issued by the

International Accounting Standards Board, or IASB, and as adopted by the EU.

These interim consolidated financial statements

do not include all the information required for full annual financial statements and should be read in conjunction with the consolidated

financial statements of the Company as of, and for the year ended, December 31, 2021.

The Company ended the period with $40.0 million

in cash and cash equivalents as of June 30, 2022, and continued to incur losses. The Company is expecting continued losses and negative

operating cash flows in the coming twelve months. Taking into account the above financial situation and on the basis of the most recent

business plan, the Company believes that it has sufficient cash to be able to continue its operations for at least the next twelve months

from the date of issuance of these financial statements, and accordingly has prepared the consolidated financial statements assuming that

it will continue as a going concern. This assessment is based on forecasts and projections within management's most recent business

plan as well as the Company's expected ability to realize cost reductions should these forecasts and projections not be met.

The Company applies the International Financial

Reporting Standards (IFRS) as issued by the IASB and as adopted by the EU. The same accounting policies, presentation and methods of computation

have been followed in these condensed financial statements as were applied in the preparation of the Company's financial statements

for the year ended December 31, 2021. No amendments to existing standards that became applicable as from January 1, 2022, have a material

impact on the consolidated financial statements or accounting policies.

The preparation of the interim condensed financial

statements in compliance with IAS 34 requires the use of certain critical accounting estimates. It also requires the Company's management

to exercise judgment in applying the Company's accounting policies. The Company has applied the same accounting policies and there

have been no material revisions to the nature and amount of estimates and judgments in its interim condensed financial statements.

The COVID-19 outbreak has impacted management's

estimates, judgments and assumptions, and could impact the Company's ability to develop business, conduct operations, and obtain

components used in its business. The situation is continuously evolving, therefore the extent to which the COVID-19 outbreak will continue

to impact business and the economy is highly uncertain and is extremely difficult to predict. Accordingly, the Company cannot accurately